Press Enter to search · ESC to close

AI × Crypto

Anthropic’s Secret Drug Lab, $3.17B Marketing Blitz, and Spy Paranoia

Anthropic is developing experimental drugs with Claude, spending $3.17B on marketing, and enforcing extreme security measures—all ahead of a record-breaking IPO. The AI giant is no longer just an AI company.

Anthropic’s Secret Drug Lab, $3.17B Marketing Blitz, and Spy Paranoia

Anthropic is no longer just an AI company. It is quietly becoming a pharmaceutical powerhouse, a marketing machine, and a security-obsessed fortress—all while preparing for what could be the largest IPO in history.

Big Pharma’s Worst Nightmare

Claude is now designing experimental drugs for rare pediatric diseases and multiple cancers. In six pharmaceutical companies, Claude has compressed three months of regulatory writing into four hours, designed 35,000 antibodies in a month, and cut genetic instruction fragments for a cancer therapy by 70% while improving lab results. Anthropic also acquired Mithril Medicine—a one-person company that used Claude to advance a muscular dystrophy therapy from concept to positive mouse results in under 18 months. Personalized medicine is the future, and Anthropic is betting that AI can crack it.

Marketing Muscle

Anthropic’s S-1 filing reveals nearly $3.17 billion spent on sales, marketing, and partnerships in the first half of 2026. The company uses a hybrid model: an internal brand team sets direction, while agencies like Mother, Initiative, and Edelman execute. Its Super Bowl debut took direct aim at OpenAI, proving Anthropic isn’t shy about confrontation. The message is clear: build it, but shout about it too.

The Spy Game

Anthropic has banned all branded merchandise and requires employees to cover visible badges and logos. The move follows concerns over espionage, foreign intelligence, and “honey traps” targeting AI employees. Staff must use privacy screens on public transit and erase whiteboards after meetings. With many foreign nationals—including top AI talent from China—Anthropic is taking no chances. CEO Dario Amodei’s personal security cost $2.7 million last year, four times his base salary.

What’s Next

Anthropic expects drugs ready for human trials by late 2028. As its IPO looms, the company’s every move will be scrutinized. But the real story may be what happens behind closed doors—the next chapter, we’re told, is even more controversial. For now, Anthropic is writing history, one headline at a time.

View original

Share
Risk notice Cointime 发布的新闻、行情、数据及其他内容仅用于信息传播和一般参考,不构成投资、法律、税务或其他专业建议。

Related Reading

Latest News

Cointime share card
Long-press image above → Save to Photos / Share
Pitch us Community Feedback